Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2016 February
  • Home
  • Archive for February, 2016

Biosortia Pharmaceuticals Introduction JLABS – San Diego

  • February 25 2016

San Diego, California (February 25, 2016) – A brief explanation of what Biosortia does, how is it achieved, and why it is meaningful. Drug discovery directly from the chemistry of unculturable aquatic microorganisms in situ. ### About Biosortia Pharmaceuticals – Biosortia has a proven and unique ability to obtain unculturable aquatic microbial consortia from the natural environment in

Continue Reading

BIOSORTIA CONTRACT GIVES RESEARCHERS ACCESS TO NATURAL PRODUCT CHEMISTRY FOR DRUG DISCOVERY EFFORTS

  • February 22 2016

Columbus, Ohio (February 22, 2016) – Biosortia Pharmaceuticals announces today a contract with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) that gives the institution’s cancer researchers access to novel natural product chemistry for the purpose of discovering and developing cancer-fighting therapeutics.

Continue Reading

RSS Industry News

  • Babies share microbiomes at nursery January 30 2026
  • Modeling diet-gut microbiome interactions and prebiotic responses in Thai adults January 28 2026
  • Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial January 28 2026
  • Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial January 28 2026
  • Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial January 28 2026
  • Large-scale capsid-mediated mobilisation of bacterial genomic DNA in the gut microbiome January 27 2026
  • Oral–gut bacterial transport drives chronic liver disease January 27 2026
  • Effector–host interactome map links type III secretion systems in healthy gut microbiomes to immune modulation January 26 2026
  • Fecal microbiome predicts treatment response after the initiation of semaglutide or empagliflozin uptake January 24 2026
  • Tree bark microbiota in climate-active gas cycling January 23 2026
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • AI, Microbiomes, & 8 Orders of Magnitude Improvement
  • Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo
  • The Billion Dollar Savings per Approved Drug
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2026. All Rights Reserved.